Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

A lawsuit against pulse oximeter manufacturers and distributors is starting to create change. But experts say the FDA needs ...

The other low-alarm-rate instrument (Masimo SET) identified both conditions equally or even more reliably than a conventional pulse oximeter.

ECG leads were placed on the infant's chest. Masimo and Nellcor oximeter sensors were randomly allocated to each foot. Measurements were collected for 10mins. Screens from the oximeters and ECG ...

Masimo, a company that says it has the most accurate pulse oximeters on the market, would happily comply with any FDA guidance, Daniel Cantillon, Masimo's chief medical officer, said in an interview.

Another vital part of the kit is a pulse oximeter, which [Aris] uses to make sure he’s getting enough oxygen. His O 2 saturation actually goes up from his baseline when the hood is on and ...

The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks ... where traditional pulse oximeters may fail. Masimo Corporation (NASDAQ:MASI ...

Masimo’s second-quarter 2024 results buoy optimism. Per management, shipments of non-invasive technology boards and instruments, excluding handheld and fingertip pulse oximeters, totaled 58,600 ...

Masimo (NASDAQ: MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The conference call to review ...

We’re always looking for interesting biohacks here on Hackaday, and this new research article describing a calibrated pulse oximeter for different skin tones really caught our attention.

The oximeter placed on his fingertip registered well above the 88% blood oxygen saturation level Skip to main content You have permission to edit this article. Edit Close Newsletter Facebook ...

Masimo, a company that says it has the most accurate pulse oximeters on the market, would happily comply with any FDA guidance, Daniel Cantillon, Masimo's chief medical officer, said in an interview.